Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

NCT07342244 is registered in ClinicalTrials.gov with Donghua Zhang as lead sponsor.

NCT NCT07342244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07342244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Donghua Zhang
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 30, 2026
Completion date
December 20, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, aml (acute myeloid leukemia)